These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-000689-38 ESTUDIO FASE III, ALEATORIZADO, DOBLE CIEGO DE TRATAMIENTO DE LA MUCOSITIS ORAL CON COCIMIENTO DE LLANTÉN VS CLORHEXIDINA AL 0,12% VS DISOLUCIÓN ACUOSA DE BICARBONATO AL 5% EN PACIENTES ONCOLÓGICOS QU... not-yet-due
Completed, but no date 2007-000456-13 Estudio fase II de Bevacizumab en combinación con Capecitabina y radioterapia como tratamiento preoperatorio en pacinetes con cáncer rectal localmente avanzado resecable. bad-data
Exempt Terminated 2008-002105-39 Estudio Piloto/Fase II aleatorizado, multicéntrico, doble ciego en neoadyuvancia de la combinación de exemestano y sunitinib en mujeres postmenopaúsicas con cáncer de mama primario, receptores hormona... not-yet-due
Completed, but no date Terminated 2010-021872-27 “Estudio de fase II de tratamiento neoadyuvante con gemcitabina, Tarceva® y oxaliplatino, seguido de quimiorradioterapia con Tarceva® y gemcitabina en pacientes con adenocarcinoma pancreático de resec... bad-data
Completed, but no date 2010-024415-14 Ensayo clínico fase II, no randomizado, para evaluar el papel de Ipilimumab en monoterapia, administrado en primera línea en pacientes afectos de melanoma uveal metastásico. "Phase II multi-center, n... bad-data
Ongoing 2011-000490-30 Phase II randomised, open-label, multicentric clinical trial of neoadjuvant treatment comprising chemotherapy and trastuzumab with or without metformin, in women with HER2/ErbB2 positive primary breas... not-yet-due
Exempt 2012-000597-38 Ensayo clínico FESGEN.DOC: Evaluación de la variabilidad interindividual en farmacocinética, eficacia y seguridad de Docetaxel en el tratamiento neoadyuvante de cáncer de mama. Estudio farmacocinético... not-yet-due
Ongoing 2013-004321-83 A randomised phase III trial comparing a strategy based on molecular analysis to the empiric strategy in patients with carcinoma of an unknoun primary (CUP) Ensayo Clínico Aleatorizaco de Fase III ... not-yet-due
Ongoing, reported early 2016-002678-11 An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer Estudio piloto, abierto, de biomarcadores de la actividad antitumora... not-yet-due
Other 2017-002505-35 BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mu... not-yet-due
Ongoing 2019-002626-67 EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE BORTEZOM... not-yet-due
Reported results Terminated 2020-001765-37 Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without ... 2020-06-26 due-trials